The substantial cardiovascular benefits observed with SGLT2 inhibitors (55% reduction in heart failure hospitalization) and GLP-1 receptor agonists (35% reduction in major adverse cardiovascular events) highlight the need to align treatment with broader cardiorenal-metabolic risk profiles, rather than focusing exclusively on glycemic control. This evidence concerns the gene SLC5A2 and heart failure.